NASDAQ : PRTA
Prothena Corporation plc — Key statistics
Healthcare · Biotechnology · Ireland
Last price 8.47 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 434.82M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 434.82M |
| Enterprise Value | 153.62M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 51.34M |
| Shares Outstanding | 51.34M |
| Shares Change (YoY) | -0.82% |
| Shares Change (QoQ) | -3.63% |
| Owned by Insiders (%) | 25.20% |
| Owned by Institutions (%) | 83.32% |
| Float | 33.40M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.97 |
| Forward PS | 13.59 |
| PB Ratio | 1.53 |
| P/TBV Ratio | 1.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 2.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 25.05 |
| Quick Ratio | 24.72 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -14.39% |
| Return on Assets (ROA) | -10.67% |
| Return on Invested Capital (ROIC) | -11.92% |
| Return on Capital Employed (ROCE) | -20.58% |
| Weighted Average Cost of Capital (WACC) | 2.60% |
| Revenue Per Employee | $813,881 |
| Profits Per Employee | -$656,597 |
| Employee Count | 67 |
| Asset Turnover | 0.16 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -358,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.29 |
| 52-Week Price Change | -20.47% |
| 50-Day Moving Average | 8.76 |
| 200-Day Moving Average | 9.24 |
| Relative Strength Index (RSI) | 48.40 |
| Average Volume (20 Days) | 557,203 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 7.94M |
| Short Previous Month | 8.01M |
| Short % of Shares Out | 15.47% |
| Short % of Float | 23.77% |
| Short Ratio (days to cover) | 13.61 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 54.53M |
| Gross Profit | -10.42M |
| Operating Income | -59.87M |
| Pretax Income | -44.35M |
| Net Income | -43.99M |
| EBITDA | -59.04M |
| EBIT | -59.87M |
| Loss Per Share | -$0.83 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 288.19M |
| Total Debt | 6.99M |
| Net Cash | 281.20M |
| Net Cash Per Share | $5.48 |
| Equity (Book Value) | 286.89M |
| Book Value Per Share | 5.54 |
| Working Capital | 280.36M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -60.05M |
| Capital Expenditures | -662,000 |
| Depreciation & Amortization | 828,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -60.71M |
| FCF Per Share | -$1.18 |
Margins
| Measure | Value |
|---|
| Gross Margin | -19.11% |
| Operating Margin | -109.79% |
| Pretax Margin | -81.33% |
| Profit Margin | -80.67% |
| EBITDA Margin | -108.27% |
| EBIT Margin | -109.79% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.82% |
| Shareholder Yield | 0.82% |
| Earnings Yield | -9.84% |
| FCF Yield | -13.96% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $21.40 |
| Price Target Difference | 152.66% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 118.54% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 13.38 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |